Morgan Stanley analyst Erin Wright lowered the firm’s price target on Humana (HUM) to $262 from $277 and keeps an Equal Weight rating on the shares. For healthcare technology and providers, the firm sees an “attractive backdrop for alpha-generation opportunities” in 2026, the analyst tells investors. Meanwhile, managed care stocks have underperformed in 2025 and are facing “another year of unprecedented policy, reimbursement, and utilization headwinds,” the analyst added in a year-ahead outlook note for the Healthcare Services group.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana awarded $7.34B to exercise Defense Health Agency contract option
- Midday Fly By: Ford takes $19.5B EV writedown, Apple expanding iPhone lineup
- Humana skewing debate over how to care for older Americans, STAT News says
- Humana Announces Leadership Changes Effective January 2026
- Humana reaffirms FY25 adjusted EPS view approx. $17, consensus $17.05